Hansa Biopharma intends to carry out a 10m Directed share issue executed by an accelerated book buil...
Redeye provides a comment on Verve’s announcement of a directed share issue which strengthens the co...
Biovica records SEK 2.3m in total net sales (22% above Q4 last year), and clinical sales increased b...
Key milestone for readiness Prolight has reported positive interim results from the ongoing patient ...
Redeye comments on Cantargia’s loan agreement with Fenja, which is positive in that it strengthens i...
Q2 report due 18 July Q2e net sales SEK 555m, EBITA SEK 79m We leave our FVR unchanged at SEK 44-59 ...
Redeye comments on Episurf Medical’s latest update regarding the FDA clearance process for the compa...
We initiate coverage of Nokian Panimo with a target price of EUR 2.
Redeye comments on Alligator Bioscience’s recent interactions with the FDA and the EMA.
Redeye re-initiates coverage of Isofol Medical, a Swedish oncology biotech company targeting the mul...
Redeye endorses today’s news that Acarix has secured a fixed reimbursement of USD300 for the CADScor...
Redeye comments on Alzecure announcing a rights issue of up to SEK58.
Enorm potential ska vägas mot stora risker i spännande gruvutvecklare.
Moberg Pharma successfully launched Teclara in Sweden last year, and the early initial feedback from...
Powercell and Robert Bosch GmbH extend their strategic partnership to address the rapidly growing Ch...
Fiskars announced a profit warning on 12 June, and now expects adjusted EBIT of EUR 90-110m for 2025...
Redeye provides a comment following Magle’s announcement that it is exploring the issuance of senior...
Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regard...
We raise '25e-'27e EBITDA by 35-40% on the recent SEK 1bn order 2025 will be a strong year: sales +1...
Redeye provides a comment on this week’s news flow, with new data on BI-1206 in solid tumours and BI...
